![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Tuesday, January 18, 2022 8:41:48 PM
Not all autologous DCs are created equal. If you or I get cancer in the future, and DCVax-l is made, part of our response will be dependent on the health and cytokine messaging (including danger signals from the tumor lysate) of our own individual DCs. Outside the body, It reaches full maturity while being pulsed with antigens from lysate derived from dead tumor cells. It migrates to the lymph node when injected. It expresses to effector t-cells and they leave to find and eliminate t-cells.
DCVax-Direct is partially matured before any exposure to antigens, and its capacity to pump out certain cytokines can be selected for and/or enhanced. Once in the tumor, the partially matured DC-Direct injected not only uptakes antigens, it also produces and responds to cytokines — killing tumor cells, directing both arms of the immune system, etc. It basically overwhelms the tumor micro-environment (guns blazing) and tells/programs itself (aka DC) this is a full combat zone. It then migrates toward lymph nodes, finishes maturing before it arrives at the lymph nodes and expresses a message to matching t-cells that holy hell has broken out. In this way, it is not compromised by tumor immunosuppressive signaling that tries to say, “nothing to see here, no expanding metastatic tumors here, these are not the droids you are looking for.” Direct, is, as Dr. Bosch states, a bit more aggressive than L. The hyper charged effector t-cells head to the tumor and other locations with only one thing on their mind…. killing tumor cells, wherever they are found.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM